Continued Access to Darunavir/Ritonavir (DRV/Rtv) in HIV-1 Infected Adults, Adolescents and Children Aged 3 Years and Above

Trial Profile

Continued Access to Darunavir/Ritonavir (DRV/Rtv) in HIV-1 Infected Adults, Adolescents and Children Aged 3 Years and Above

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Darunavir (Primary) ; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Janssen R&D Ireland; Janssen Sciences Ireland UC
  • Most Recent Events

    • 27 Feb 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2021.
    • 27 Feb 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2021.
    • 16 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top